The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.

Expert review of anticancer therapy

Volumn 13, Issue 9, 2013, Pages 1021-1033

  Stenner Liewen, F ^a   Grunwald V ^b   Greil, R ^b   Porta, C ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; HUMAN; KIDNEY NEOPLASMS;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84898519763     PISSN: None     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.833684     Document Type: Review

References (0)